Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ 101 Glacier Point, Suite A San Rafael, CA 94901 (Address of principal executive offices) (Zip Code) Indicate by check mark whether the ...

[Recent Highlights and Accomplishments](index=1&type=section&id=Recent%20Highlights%20and%20Accomplishments) Ekso Bionics achieved key Q1 2024 milestones, including final CMS payment determination for Ekso Indego Personal and 29 EksoHealth unit sales - Received **final payment determination** from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal, a **key milestone** for the company's commercial strategy[3](index=3&type=chunk)[12](index=12&type=chunk) - The company's **strategic focus** is on developing the market for Indego Personal and strengthening relationships with network operators for its Enterprise devices to **drive growth**[3](index=3&type=chunk) - Sold a total of **29 EksoHealth units** during the first quarter of 2024[4](index=4&type=chunk)[12](index=12&type=chunk) [First Quarter 2024 Financial Performance](index=1&type=section&id=First%20Quarter%202024%20Financial%20Performance) Ekso Bionics reported Q1 2024 revenue of $3.8 million, improved gross margin to 52%, and reduced net loss to $3.4 million Q1 2024 vs Q1 2023 Key Financial Metrics | Metric | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | Revenue (Millions USD) | $3.8 | $4.1 | -7.3% | | Gross Profit (Millions USD) | $2.0 | $2.0 | 0% | | Gross Margin (%) | 52% | 49% | +3 p.p. | | Net Loss (Millions USD) | $3.4 | $4.4 | Improved | | Net Loss per Share (USD) | $0.20 | $0.33 | Improved | - The improvement in gross margin was primarily due to **lower EksoHealth device and service costs**[5](index=5&type=chunk) - **Operating expenses decreased**, with sales and marketing expenses falling to $1.8 million from $2.1 million due to **lower headcount**, and general and administrative expenses decreasing to $2.3 million from $3.2 million due to **reduced legal activity**, **lower headcount**, and the **absence of prior-year acquisition costs**[6](index=6&type=chunk)[7](index=7&type=chunk) [Financial Condition](index=1&type=section&id=Financial%20Condition) Ekso Bionics maintained a stable financial position as of March 31, 2024, with $8.8 million cash and reduced total liabilities Balance Sheet Highlights (as of March 31, 2024) | Metric | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and restricted cash (Millions USD) | $8.8 | $8.6 | | Total Assets (Millions USD) | $29.0 | $28.9 | | Total Liabilities (Millions USD) | $14.9 | $16.3 | | Total Stockholders' Equity (Millions USD) | $14.1 | $12.6 | [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) Detailed consolidated financial statements for Q1 2024 show Ekso Bionics' financial position with $29.0 million in assets and a $3.4 million net loss [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets were $28.96 million, with liabilities decreasing to $14.91 million and equity increasing to $14.05 million Condensed Consolidated Balance Sheets (In thousands) | | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Total current assets (Thousands USD)** | **$20,516** | **$20,208** | | Total assets (Thousands USD) | $28,957 | $28,918 | | **Total current liabilities (Thousands USD)** | **$7,312** | **$8,117** | | Total liabilities (Thousands USD) | $14,906 | $16,312 | | Total stockholders' equity (Thousands USD) | $14,051 | $12,606 | | **Total liabilities and stockholders' equity (Thousands USD)** | **$28,957** | **$28,918** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2024 operations reported $3.76 million revenue, $1.95 million gross profit, and a net loss of $3.43 million or $0.20 per share Condensed Consolidated Statements of Operations (In thousands, except per share amounts) | | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Revenue (Thousands USD) | $3,756 | $4,122 | | Gross profit (Thousands USD) | $1,951 | $2,000 | | Total operating expenses (Thousands USD) | $5,207 | $6,448 | | Loss from operations (Thousands USD) | $(3,256) | $(4,448) | | Net loss (Thousands USD) | $(3,429) | $(15,080) | | Net loss per share, basic and diluted (USD) | $(0.20) | $(0.33) |

SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding ("PDAC") contractor for the Centers for Medicare & Medicaid Services ("CMS") has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024. As previously announced ...

Financial Data and Key Metrics Changes - Revenue for the full year 2023 increased by 42% to $18.3 million compared to $12.9 million in 2022, primarily driven by an increase in EksoHealth device sales [1][12] - Operating expenses for 2023 were $24.2 million, up from $21.8 million in the prior year, mainly due to the acquisition and integration of HMC [2] - Net loss applicable to common stockholders for 2023 was $15.2 million or $1.10 per share, compared to a net loss of $15.1 million or $1.16 per share in 2022 [2] - Gross profit for the full year was $9.1 million, with a gross margin of approximately 50%, compared to $6.2 million and a gross margin of 48% in 2022 [5] Business Line Data and Key Metrics Changes - The company sold 151 EksoHealth devices in 2023, a 51% increase from 2022 levels [19] - In Q4 2023, revenue was $4.8 million, a 36% increase from $3.6 million in Q4 2022, driven by increased sales of EksoNR and Indego devices [13][39] - Gross profit for Q4 was $2.4 million, with a gross margin of approximately 49%, compared to $1.7 million and a gross margin of 47% in Q4 2022 [39] Market Data and Key Metrics Changes - The company achieved solid performance in EMEA and APAC regions, with increased sales volume supported by a strong distribution network [25] - Multiunit EksoNR sales were generated across Eastern Europe in Q4, indicating growth in international markets [25] Company Strategy and Development Direction - The company is focused on building a scalable go-to-market strategy and strengthening its distribution network to drive sustained growth for EksoHealth devices [19][32] - The launch of GaitCoach software for EksoNR aims to improve user experience and increase device utilization [20][21] - The company is committed to maximizing EVO's placement in large industrial settings, despite modest revenue contributions from the industrial segment [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the 2024 business outlook, building on the momentum generated in 2023 [67] - The company is focused on optimizing expense and inventory management processes to scale its business efficiently [32][67] - Management highlighted the importance of supporting CMS in providing additional pricing details for reimbursement determinations [51][70] Other Important Information - Operating cash burn for Q4 was $1.6 million, down from $3.7 million in Q4 2022 [4] - Cash used in operating activities for the fiscal year was $12.1 million, with cash on hand of $8.6 million as of December 31, 2023 [42] Q&A Session Summary Question: Update on Indego pricing and CMS discussions - Management confirmed ongoing discussions with CMS regarding final pricing and the need for additional commercial pricing evidence to support reimbursement claims [49][51] Question: Sustainability of sales growth - Management indicated that the growth in sales is supported by a strong pipeline and scalable strategies, with increased multiunit orders from integrated delivery networks [54][55] Question: Operating expenses and margin expansion - Management noted that cost containment programs are in place and expressed confidence in achieving operating margin expansion in 2024 [46][58] Question: Referral pathways for personal units - Management discussed the importance of building strong relationships with healthcare providers to facilitate prescriptions and claims reimbursement [71][74]

Ekso Bionics (EKSO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this robotic exoskeleton company would post a loss of $0.31 per share when it actually produced a loss of $0.24, delivering a surprise of 22.58%.Over the last four quarters, the comp ...

Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-yearSold a total of 151 EksoHealth units for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Nevada 99-0 ...

The price trend for Ekso Bionics (EKSO) has been bearish lately and the stock has lost 8.9% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street ana ...

Ekso Bionics (NASDAQ:EKSO) stock is on the rise Friday without any clear news from the exoskeleton company this morning.There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today. On that same note, no analysts have offered coverage of the stock today that would have EKSO shares climbing higher.The only recent news worth noting about EKSO stock comes from an analyst update on Monday. H.C. Wainwright analysts increased the price target ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call October 26, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2023 Financial Results Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will ...